quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:05:14·486d
SECFiling
Cyclo Therapeutics Inc. logo

Cyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

CYTH· Cyclo Therapeutics Inc.
Health Care
Original source

Companies

  • CYTH
    Cyclo Therapeutics Inc.
    Health Care

Related

  • SEC381d
    SEC Form 15-12G filed by Cyclo Therapeutics Inc.
  • SEC393d
    Cyclo Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR393d
    Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
  • SEC395d
    Cyclo Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
  • PR406d
    Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
  • SEC413d
    Cyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
  • INSIDER416d
    Director Conkling William was granted 27,654 shares, increasing direct ownership by 55% to 77,884 units (SEC Form 4)
  • INSIDER416d
    Director Wong Vivien was granted 25,140 shares, increasing direct ownership by 63% to 64,853 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022